Clinical Trials Directory

Trials / Sponsors / Aadi Bioscience, Inc.

Aadi Bioscience, Inc.

Industry · 11 registered clinical trials — 3 currently recruiting.

StatusTrialPhaseStarted
RecruitingTrial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endom
Endometrial Cancer, Endometrioid Tumor, Cancer
Phase 22023-12-28
RecruitingTrial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestin
Neuroendocrine Tumors, NET, Pancreatic Neuroendocrine Tumor
Phase 22023-11-07
RecruitingDose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced
Tumor, Solid, Tumor, Advanced Solid Tumor
Phase 12022-11-23
WithdrawnABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome
Leigh Syndrome
Phase 22022-04-30
Active Not RecruitingPhase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in T
Tumor, Tumor, Solid, Metastasis
Phase 22022-02-15
CompletedNab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma
Phase 22018-08-01
CompletedNab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Col
Colorectal Cancer Metastatic
Phase 1 / Phase 22018-07-01
CompletedPhase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension
Pulmonary Hypertension
Phase 12017-04-01
CompletedA Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa
Malignant PEComa
Phase 22015-10-01
CompletedPhase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Non-muscle Invasive Bladder Cancer (NMIBC)
Phase 1 / Phase 22014-04-09
Approved For MarketingExpanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Gene
PEComa, Malignant, TSC1, TSC2
——